HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Kelly, K. Search for Related Content PubMed PubMed Citation Articles by Kelly, K.

New Chemotherapy Agents for Small Cell Lung Cancer^*

^* From the University of Colorado Health Sciences Center, Denver, CO.

Correspondence to: Karen Kelly, MD, Associate Professor of Medicine, Division of Medical Oncology B171, 4200 East Ninth Ave, Denver, CO 80262; e-mail: karen.kelly{at}uchsc.edu

Background: Approximately 45,000 new cases of small cell lung cancer (SCLC) will be diagnosed in the United States this year. Combination chemotherapy is the cornerstone of treatment for all stages of this disease and results in high response rates (65 to 85%), leading to a meaningful survival advantage for these patients. Patients with limited-stage disease enjoy a median survival of 10 to 15 months with chemotherapy, as compared to 3 months without drug therapy. With addition of chest radiotherapy, survival is further prolonged to 12 to 20 months. Patients with extensive-stage disease experience an average survival of 1.5 months without chemotherapy and 7 to 11 months with chemotherapy. However, no further improvement in survival has been demonstrated since combination chemotherapy regimens were introduced in the late 1970s and early 1980s, despite evaluating numerous strategies; the 5-year survival for all patients remains dismal at 5%. Clearly, new chemotherapy agents with novel mechanisms of action are needed.

Focus: This article will review the experience to date with six new agents that are active against SCLC. It includes two taxanes (paclitaxel and docetaxel), vinorelbine, two camptothecin derivatives (topotecan and irinotecan), and gemcitabine. Single-agent activity as well as combination regimens with other agents and radiotherapy will be discussed. The role of maintenance therapy with oral matrix metalloproteinase inhibitors also is evaluated.

Key Words: carboplatin • cisplatin • gemcitabine • small cell lung cancer • survival • taxanes • topotecan • vinorelbine

This article has been cited by other articles:

				A. Granetzny, A. Boseila, W. Wagner, G. Krukemeyer, U. Vogt, E. Hecker, O. M. Koch, and F. Klinke Surgery in the tri-modality treatment of small cell lung cancer. Stage-dependent survival. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 212 - 216. [Abstract] [Full Text] [PDF]

				D. De Ruysscher, M. Pijls-Johannesma, J. Vansteenkiste, A. Kester, I. Rutten, and P. Lambin Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer Ann. Onc., April 1, 2006; 17(4): 543 - 552. [Abstract] [Full Text] [PDF]

				A. Ardizzoni Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update Oncologist, December 1, 2004; 9(suppl_6): 4 - 13. [Abstract] [Full Text] [PDF]

				J. Treat, C. H. Huang, S. R. Lane, and J. Levin Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status Oncologist, April 1, 2004; 9(2): 173 - 181. [Abstract] [Full Text] [PDF]

				K. Osterlind Chemotherapy in small cell lung cancer Eur. Respir. J., December 1, 2001; 18(6): 1026 - 1043. [Abstract] [Full Text] [PDF]

				N. V. Koshkina, J. C. Waldrep, L. E. Roberts, E. Golunski, S. Melton, and V. Knight Paclitaxel Liposome Aerosol Treatment Induces Inhibition of Pulmonary Metastases in Murine Renal Carcinoma Model Clin. Cancer Res., October 1, 2001; 7(10): 3258 - 3262. [Abstract] [Full Text] [PDF]

				R. M. Bremnes, S. Sundstrom, J. Vilsvik, and U. Aasebo Multicenter Phase II Trial of Paclitaxel, Cisplatin, and Etoposide With Concurrent Radiation for Limited-Stage Small-Cell Lung Cancer J. Clin. Oncol., August 1, 2001; 19(15): 3532 - 3538. [Abstract] [Full Text] [PDF]

				K. Kelly, L. Lovato, P. A. Bunn Jr., R. B. Livingston, J. Zangmeister, S. A. Taylor, D. Roychowdhury, J. J. Crowley, and D. R. Gandara Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer: A Phase II Trial of the Southwest Oncology Group Clin. Cancer Res., August 1, 2001; 7(8): 2325 - 2329. [Abstract] [Full Text] [PDF]